Q9986 HCPCS Level II code: Injection, hydroxyprogesterone caproate, (makena), 10 mg
CMS terminated Q9986: its last date of service was Dec 31, 2017. It stays here for looking up older claims; newer services need a current code.
Official description
Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mg
Short description: Makena, 10 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q9986 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Cross-reference
- See J1726
- Added
- Jul 1, 2017
- Terminated after
- Dec 31, 2017
Where Q9986 sits
- 1Q codesTemporary codes
- 2Terminated Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q9986 still valid?
No. CMS terminated Q9986; its last date of service was Dec 31, 2017. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q9986?
CMS lists Q9986’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9986
All Q codesQ9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mgQ9981Rolapitant, oral, 1 mgQ9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesQ9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuriesQ9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mgQ9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgQ9987Pathogen(s) test for plateletsQ9988Platelets, pheresis, pathogen-reduced, each unitQ9989Ustekinumab, for intravenous injection, 1 mgQ9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mgQ9992Injection, buprenorphine extended-release (sublocade), greater than 100 mgQ9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg